Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Google Secures Pentagon AI Deal for Classified Projects 
China Manufacturing PMI Beats Forecasts in April Amid Weak Domestic Demand 
US Stock Futures Rise as S&P 500 and Nasdaq Hit Record Highs Amid Earnings Optimism and Iran Tensions 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
AI Stocks Rally in Asia as Oil Surge and Hawkish Central Banks Shake Global Markets 
Oil Prices Ease but Remain Set for Strong April Gains Amid Middle East Tensions 
Yen Weakens After Intervention Spike as Dollar Stabilizes Amid Global Tensions 
Tokyo Inflation Slows Despite Energy Pressures and BOJ Policy Outlook 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
US Stock Futures Mixed as Fed Holds Rates, Oil Prices Surge, and Big Tech Earnings Drive Market Moves 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Oil Prices Surge Amid U.S.-Iran Tensions and Supply Disruption Fears 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Gold Prices Slip Amid Iran Tensions and Rising Rate Concerns 
China Factory Activity Extends Growth in April Despite Global Pressures 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Samsung Biologics and AstraZeneca are reportedly dissolving their biosimilar joint venture. They have formed the Archigen Biotech for the JV, and now this is being shut down.
An official of Samsung Biologics, the biotech unit of the Samsung Group, said on Tuesday, May 24, that it has decided to end its joint venture with the British-Swedish multinational pharmaceutical and biotechnology company due to the suspension of the development of a biosimilar product.
According to Yonhap News Agency, the decision came two months after the Samsung Biologics’ board agreed with the liquidation of Archigen Biotech Ltd. The said company was set up in 2014 via a 50-50 joint venture with AstraZeneca.
When it was first established, Archigen Biotech was working on the development of SAIT101, a biosimilar of Rituximab, a monoclonal antibody medication used for the treatment of lymphoma. It was explained that a biosimilar is a similar duplication of an already existing and approved biologic drug.
However, both Samsung Biologics and AstraZeneca halted the biosimilar program and scrapped the Rituxan copy project. It was revealed to have been actually discontinued in the second half of 2020 after competitors such as Celltrion Inc. started marketing the same products.
Fierce Pharma further reported that Archigen Biotech already launched a phase 3 trial of the SAIT101 in June 2016, but the works have been progressing very slowly. In fact, the original target date for the completion of the project has already been pushed back by more than a year.
The results of the trial were revealed last month and showed that the Rituxan biosimilar medication generated a response in 66.3% of patients, which is on par with the 70.6% posted by the originator.
But then, another issue has cropped up - the market for this product is already crowded with other biotech firms introducing their own biosimilars, with some already being sold. Aside from Celltrion, Achigen Biotech is also competing with Teva Pharmaceuticals, Pfizer, Mylan, and Novartis’ Sandoz. With all of these firms, it became apparent to Samsung Biologics and AstraZeneca that the best move now is to scrap their own Rituxan biosimilar product.
